CSNK1E Sustains Stem-like Drug Persistence in Diffuse Large B-cell Lymphoma - PubMed
3 hours ago
- #Drug Resistance
- #CSNK1E
- #DLBCL
- Relapsed or refractory (R/R) disease occurs in up to 40% of diffuse large B-cell lymphoma (DLBCL) patients post first-line immunochemotherapy.
- Drug-persistent cells in DLBCL exhibit a less-differentiated state and adopt a memory B cell-like program with enhanced stem-like properties.
- These stem-like drug-persistent cells show increased clonogenicity in vitro and tumor-initiating capacity in vivo.
- CSNK1E, a WNT signaling regulator, is upregulated in drug-persistent cells, partly via the APRIL-TNFRSF13B axis activation.
- Inhibition of CSNK1E reduces growth and tumor-initiating capacity of drug-persistent cells and enhances R-CHOP-based treatment efficacy.
- The study identifies CSNK1E as a therapeutic target to improve DLBCL treatment outcomes.